Rationale: Emphysema is mainly known for the complex inflammatory processes associated with its development. In addition to lung inflammation, it is now accepted that increased alveolar cell apoptosis is also part of emphysema pathophysiology. However, little is known about the mechanisms involved in alveolar apoptosis. We postulate that oxidative stress and proinflammatory cytokines could lead to p53 accumulation, Bax/Bcl-x L ratio elevation, and higher tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor levels in the emphysematous lung. Objectives: To evaluate the expression of p53, Bax, Bcl-x L , TRAIL, and TRAIL receptors in lung parenchyma from nonemphysematous nonsmokers and smokers and emphysematous smokers and exsmokers and to determine whether H 2 O 2 and/or TNF can modulate the expression of these apoptotic proteins. Methods: p53, Bax, Bcl-x L , and TRAIL receptor protein levels in lung parenchyma were measured by Western blot, and TRAIL mRNA levels were measured by real-time polymerase chain reaction. Changes in TRAIL receptor, Bax, Bcl-x L , and p53 protein levels after in vitro H 2 O 2 and/or TNF stimulation of A549 cells were also assessed by Western blot. Measurements and Main Results: The p53 protein levels, the Bax/Bcl-x L ratio, and TRAIL receptors 1, 2, and 3 protein levels were significantly higher in subjects with emphysema. Moreover, they were also increased after H 2 O 2 and TNF treatments of A549 cells. Conclusions: These findings suggest that oxidative stress and proinflammatory cytokines may be involved in the elevation of p53 levels, the Bax/Bcl-x L ratio, and TRAIL receptor levels, new mechanisms that may be implicated in the increased alveolar cell apoptosis that occurs in emphysema.
Chronic obstructive pulmonary disease (COPD) is associated with cigarette smoking. Among the features of COPD, emphysema is characterized by a loss of alveolar integrity leading to an alveolar space enlargement and a decrease in diffusion capacity (1) . The accumulation of immune cells (e.g., neutrophils, macrophages, CD8 1 T lymphocytes) and the increase in cytokine (e.g., tumor necrosis factor [TNF], IFN-g) and chemokine (e.g., CXCL10) levels in the emphysematous lung (2) revealed that emphysema is a complex inflammatory disease.
In addition to inflammation, increased alveolar apoptosis has been linked to the development of emphysema (3) (4) (5) (6) . In fact, emphysematous alveolar tissue presents higher levels of apoptosis markers, such as fragmented DNA (3) (4) (5) (6) , active caspase-3 (6) , and cleaved poly (ADP-ribose) polymerase (PARP) (6) compared with normal alveolar tissue. However, the main cause, mechanisms, and involvement of apoptosis in alveoli loss observed in emphysema remain to be clarified.
The oxidative stress caused by cigarette smoke and the inflammatory burden has been well established in the emphysematous lung (7) . Oxidative stress can damage DNA (8) and lead to the activation of transcription factors such as p53 (9) , which influence cell survival. p53 is strongly linked to the DNA damage response through the up-regulation of proapoptotic factors such as Bax, Puma, Noxa, and Fas (10) . TNF-related apoptosisinducing ligand (TRAIL) receptors are also p53 transcriptional targets (11) . TRAIL, a member of the TNF family, has two proapoptotic receptors (TRAIL-R1 and TRAIL-R2) and two nonapoptotic receptors (TRAIL-R3 and TRAIL-R4) (11) . The TRAIL apoptotic system has been well studied in cancer and is believed to be implicated in neurodegenerative pathologies, such as Alzheimer's disease, where apoptosis is involved (12, 13) . In addition to p53, TRAIL receptors can be up-regulated after nuclear factor-kB activation (14) , an important transcription factor that is induced by cytokines like TNF (15) , and by oxidative stress (16) . To the best of our knowledge, no data are available on p53 activation or on TRAIL system modulation in emphysema, even if it has been reported that more alveolar cells express Bax in subjects with emphysema (4, 6) . In the present study, we hypothesized that factors at play in emphysema, such as oxidative stress and inflammatory mediators, lead to p53 activation, Bax/ Bcl-x L ratio elevation (proapoptotic balance), and TRAIL receptor up-regulation.
Our objectives were to compare p53, Bax, Bcl-x L , TRAIL, and TRAIL receptor expressions in lung parenchyma samples obtained from nonemphysematous nonsmokers and smokers and in smokers and ex-smokers with emphysema, and to evaluate their expression in A549 cells after hydrogen peroxide (H 2 O 2 ) and/or TNF treatments. We found that p53 protein levels, the Bax/Bcl-x L ratio, and TRAIL-R1, TRAIL-R2, and TRAIL-R3 protein levels were higher in subjects with emphysema. Moreover, H 2 O 2 increased p53 protein levels, the Bax/Bcl-x L ratio, and TRAIL-R1, TRAIL-R2, and TRAIL-R3 protein levels in A549 cells, whereas TNF increased TRAIL-R1 and TRAIL-R2 levels. Some results contained in this study have been previously reported in the form of abstracts (17, 18) .
METHODS Human Lung Samples
Human lung parenchyma samples were provided by the Banque de Tissus de l'Hô pital Laval (Quebec City, Canada). The samples, which were obtained from tumor resection, were located far from the tumor and analyzed by a pathologist. Fifty-two subjects were included in the study: 13 nonemphysematous nonsmokers, 14 nonemphysematous smokers, 13 smokers with emphysema, and 12 ex-smokers with emphysema. All subjects had to be between 50 and 75 years old and the smoking history of smokers and ex-smokers had to be greater than 15 pack-years. Subjects with emphysema were classified using the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification (19) . Presence or absence of emphysema was confirmed by computed tomography scan analysis for all subjects. Subjects were matched for age and smoking history. The Hô pital Laval Research Ethics Committee approved the study and all subjects provided written consent.
Lung Parenchyma Processing for Protein Analyses
Human lung parenchyma samples were homogenized in ice-cold lysis buffer with a Potter-Elvehjem tissue grinder before protein quantification. The method is described in the online supplement.
Cell Culture and Stimulations
The commercial alveolar epithelial cell line A549 was purchased from the American Type Culture Collection (ATCC, Manassas, VA) and grown in Dulbecco's modified Eagle medium (Invitrogen, Burlington, ON, Canada) with 10% fetal bovine serum (Cansera; PAA Laboratories, Etobicoke, ON, Canada). Cells were plated in six-well plates in a humidified 95% air/5% CO 2 atmosphere. Confluent culture were starved overnight in serum-free medium and stimulated with H 2 O 2 (0, 200, 500, 1,000 mM) (Laboratoire Mat, Quebec City, PQ, Canada) and/or recombinant human TNF (0, 1, 10, 100 ng/ml) (Serotec, Raleigh, NC) for 2, 6, 12, and 24 hours. Cells were lysed with 70 ml of lysis buffer (150 mM NaCl; 1 mM ethylenediamine tetraacetic acid; 25 mM Tris-HCl, pH 8.0; 1% Triton-X100; 0.5 mM phenylmethylsulfonylfluoride) and proteins quantified with DC Protein Assay (Biorad, Hercules, CA) before Western blotting. All experiments were repeated three times.
Western Blot
Western blot was used to evaluate p53, Bax, Bcl-x L , TRAIL receptor, and b-actin protein levels in lung parenchyma homogenates and A549 cell lysates. The method is described in the online supplement.
Immunohistochemistry
Immunochemical staining was used to evaluate the localization of TRAIL-R1, TRAIL-R2, and TRAIL-R3 in the lung parenchyma. The method is described in the online supplement.
Lung Parenchyma RNA Extraction and Real-Time Polymerase Chain Reaction Analyses Total RNA was extracted from lung parenchyma samples, quantified, reverse transcribed, and analyzed by real-time polymerase chain reaction (PCR) for TRAIL and 18S rRNA expression. A detailed method is provided in the online supplement.
The 2 DDCt method was used to quantify differences in TRAIL mRNA expression in the lung samples (20) . On the basis of the 18S rRNA crossing threshold (Ct), the DCt of each gene was determined for each subject. Then, for each group of subject, the mean expression of each gene was compared with the nonemphysematous nonsmoker group that represents the baseline expression. PCR efficiency was confirmed to ensure that amplification rate was comparable to 18S rRNA.
Statistical Analysis
Data from human lung parenchyma samples (ex vivo study) and the A549 cell stimulations (in vitro study) were compared using one-way analysis of variance followed by, if P , 0.05, a Tukey-Kramer test. Correlations were evaluated using Pearson's test and the significance using a one-sample t test. A significant difference was assumed when P values were lower than 0.05.
RESULTS

Ex Vivo Study
Clinical findings. The characteristics of the subjects are presented in Table 1 . The mean age and smoking history of the four groups were similar (except for the smoking history of nonsmokers). Smokers and ex-smokers with emphysema had moderate airflow obstruction with a mean FEV 1 at 57% of predicted value (39-69%) and 50% of predicted value (19-71%), respectively. Diffusion capacity of carbon monoxide (DL CO ) was reduced in smokers and ex-smokers with emphysema with a mean value at 50% of predicted (16-63%) and 54% of predicted (26-71%), respectively. Most subjects with emphysema had stage II and III disease according to GOLD classification. Nonemphysematous smokers and nonsmokers had normal lung function.
p53, Bax, and Bcl-x L protein expression in lung parenchyma. p53 protein levels were significantly higher in lung parenchyma samples from subjects with emphysema (both smokers and exsmokers) than in samples from nonemphysematous nonsmokers ( Figure 1A ) and significantly correlate with FEV 1 (r 5 0.44, P , 0.01) ( Figure 1E ), DL CO (r 5 0.32, P , 0.05) (data not shown), and FEV 1 /FVC (r 5 0.42, P , 0.01) (data not shown). Bax protein levels were significantly higher in tissue samples from subjects with emphysema (both smokers and ex-smokers) than in samples from nonemphysematous smokers ( Figure 1B) ; Bclx L protein levels were significantly higher in tissue samples from nonemphysematous smokers than in those from nonemphysematous nonsmokers ( Figure 1C) . Thus, the Bax/Bcl-x L ratio was found to be significantly higher in lung parenchyma samples from subjects with emphysema (both smokers and ex-smokers) than in samples from nonemphysematous smokers ( Figure 1D ). TRAIL mRNA and TRAIL receptor protein expression in the lung parenchyma. TRAIL-R1 levels were significantly higher in smokers and ex-smokers with emphysema than in nonemphysematous nonsmokers (Figure 2A ). TRAIL-R2 levels ( Figure  2A ) were significantly higher in subjects with emphysema (smokers and ex-smokers as a single group) than in nonemphysematous nonsmokers. TRAIL-R3 levels ( Figure 2B ) were significantly higher in smokers and ex-smokers with emphysema than in nonemphysematous smokers and nonsmokers. There were no significant differences in TRAIL-R4 levels ( Figure 2B ). Expression levels of TRAIL-R1, TRAIL-R2, and TRAIL-R3 were strongly related to each other (TRAIL-R1 vs. TRAIL-R2, r 5 0.87, P , 0.001 [ Figure 2C ]; TRAIL-R1 vs. TRAIL-R3, r 5 0.77, P , 0.001; TRAIL-R2 vs. TRAIL-R3, r 5 0.68, P , 0.001 [data not shown]). TRAIL-R1, TRAIL-R2, and TRAIL-R3 levels were also correlated with p53 levels (TRAIL-R1 vs. p53, r 5 0.67, P , 0.001 [ Figure 2D ]; TRAIL-R2 vs. p53, r 5 0.59, P , 0.01 [data not shown]; TRAIL-R3 vs. p53, r 5 0.66, P , 0.001 [data not shown]). In addition, TRAIL mRNA expression ( Figure 2E ) was significantly lower (n 5 5 per group) in the lung parenchyma of smokers with and without emphysema than in that of nonemphysematous nonsmokers.
TRAIL receptor localization in the lung parenchyma. Immunochemical staining revealed that TRAIL-R1, TRAIL-R2, and TRAIL-R3 were widely expressed in the lung parenchyma of all analyzed subjects (alveolar, endothelial, and immune cells) (6 nonemphysematous nonsmokers, 6 nonemphysematous smokers, 6 smokers with emphysema, and 6 ex-smokers with emphysema). When immune cells showed high staining levels, alveolar cells outnumbered immune cells regardless of the pathologic state ( Figure 3 ).
In Vitro Study
Effects of H 2 O 2 on p53, Bax, Bcl-x L , and TRAIL receptor protein levels in A549 cells. We found that H 2 O 2 induced the accumulation of p53 protein ( Figure 4D ) and up-regulated TRAIL-R1 ( Figure 4A ), TRAIL-R2 ( Figure 4B ), and TRAIL-R3 ( Figure  4C ), but not TRAIL-R4 (data not shown), expression in A549 cells after 2, 6, and 12 hours. Bax protein levels only increased after 24 hours when the A549 cells were treated with 200 and 500 mM H 2 O 2 , whereas Bcl-x L levels remained unchanged, resulting in an increase in the Bax/Bcl-x L ratio ( Figure 5 ). p53 levels and TRAIL-R1, TRAIL-R2, and TRAIL-R3 reached their maximum after 6 hours of treatment with 500 mM H 2 O 2 , whereas a 24-hour treatment with 200 mM H 2 O 2 produced the largest change in the Bax/Bcl-x L ratio.
Effects of TNF on TRAIL receptor protein levels in A549 cells. TNF increased the expression of TRAIL-R1 and TRAIL-R2 proteins in A549 cells (Figure 6 ). TRAIL-R1 expression was significantly increased after 2 hours of treatment with 100 ng/ml of TNF, whereas all TNF concentrations increased TRAIL-R1 expression after 6 and 12 hours of treatment. TRAIL-R2 expression was significantly increased after 2, 6, and 12 hours of treatment with 10 and 100 ng/ml of TNF. TNF treatment had no effect on TRAIL-R3 and TRAIL-R4 expression (data not shown).
Combined effects of H 2 O 2 and TNF on TRAIL receptor protein levels in A549 cells. TRAIL-R1, TRAIL-R2, and TRAIL-R3 protein levels increased after the combined treatment with H 2 O 2 (500 mM) and TNF (10 ng/ml) for 12 hours (Figure 7) . No synergistic or antagonistic effects were observed as the combination resulted in an equivalent effect induced by the most potent stimulator (TNF for TRAIL-R1 and H 2 O 2 for TRAIL-R3). 
05).
White horizontal bars at the bottom of (A) through (D) show that the y axis has been truncated. (E) Correlation between FEV 1 and p53 protein level in subjects from all groups. Patients from all four groups were pooled into a single cohort. Each patient is represented by a symbol.
DISCUSSION
In this study, to our knowledge, we demonstrated for the first time that p53 levels, the Bax/Bcl-x L ratio, and TRAIL-R1, TRAIL-R2, and TRAIL-R3 levels were higher in lung parenchyma samples from subjects with emphysema than in those from nonemphysematous subjects. Moreover, using in vitro cultures of A549 cells (alveolar epithelial cell line), we demonstrated that H 2 O 2 and TNF, two important mediators involved in emphysema development, caused similar changes. These observations demonstrate the potential involvement of oxidative stress and inflammation in the increased p53 levels, Bax/Bcl-x L ratio, and TRAIL-R1, TRAIL-R2, and TRAIL-R3 levels in the emphysematous lung.
The different subject groups of the present study, nonemphysematous nonsmokers, nonemphysematous smokers, smokers with emphysema, and ex-smokers with emphysema, gave us the opportunity to compare the effects of cigarette smoking (nonemphysematous nonsmokers vs. nonemphysematous smokers), emphysema (nonemphysematous smokers vs. smokers with emphysema), and smoking cessation (smokers with emphysema vs. ex-smokers with emphysema) on the expression of TRAIL receptor, p53, Bax, and Bcl-x L . In fact, most of the observed modulations were attributable to emphysema and, interestingly, were not affected by smoking cessation once the disease is established.
p53 accumulation/activation in the emphysematous lung parenchyma ( Figure 1A) is extremely relevant to the pathogenesis of the disease because p53 is closely associated with many apoptotic mechanisms, mainly those related to mitochondriadependent apoptosis, such as Bax up-regulation (10) . Cigarette smoke extract has been shown to induce p53 activation in normal human lung fibroblasts (21) and rats exposed to cigarette smoke present higher levels of activated p53 and Bax in the alveolar tissue (22) . However, the fact that p53 levels and that Bax/Bcl-x L ratio were higher in smokers with emphysema than in nonemphysematous smokers and that, even with smoking cessation, p53 levels and Bax/Bcl-x L ratio remained elevated in ex-smokers with emphysema suggest that the inflammation associated with emphysema that persists after smoking cessation may be involved in the increase and the maintenance of p53 levels and the Bax/Bclx L ratio. Macrophages and neutrophils, which are present in higher numbers in the lung of subjects with emphysema (2), produce large quantities of reactive oxygen species that cause oxidative stress (7) . We showed in vitro that oxidative stress alone (H 2 O 2 ) (Figures 4 and 5) induces p53 activation and increases the Bax/Bcl-x L ratio in A549 cells, suggesting that oxidative stress may be responsible for the high p53 levels and Bax/Bcl-x L ratios in smokers and ex-smokers with emphysema.
Like p53 levels and the Bax/Bcl-x L ratio, the expression of TRAIL-R1, TRAIL-R2, and TRAIL-R3 proteins was also higher in the lung parenchyma of subjects with emphysema despite smoking cessation (Figures 2A and 2B ). Immune cells were not responsible for this increase, because they were in the minority compared with alveolar cells (Figure 3) . Moreover, they do not overexpress TRAIL receptors upon activation (23, 24) . Thus, we can say that alveolar cells are responsible for the differential expression of TRAIL receptors that we observed in lung parenchyma. In addition, we observed that the expression of TRAIL-R1, TRAIL-R2, and TRAIL-R3 was correlated in all four groups ( Figure 2C ; example for TRAIL-R1 and TRAIL-R2), which suggests that the higher expression of these three TRAIL receptors in subjects with emphysema may be regulated by the same pathway(s). In line with those findings, TRAIL-R1, TRAIL-R2, and TRAIL-R3, but not TRAIL-R4, expression was associated with p53 levels in all groups ( Figure 2D ). We demonstrated in vitro that H 2 O 2 can up-regulate TRAIL-R1, TRAIL-R2, and TRAIL-R3 in A549 cells, whereas TNF up-regulates TRAIL-R1 and TRAIL-R2 protein expression. Moreover, stimulation of A549 cells with both H 2 O 2 and TNF resulted in the same TRAIL receptor up-regulation pattern observed in subjects with emphysema ex vivo. These findings on TRAIL receptor modulation by H 2 O 2 and TNF in A549 cells could explain the concomitant increase of TRAIL-R1, TRAIL-R2, and TRAIL-R3 expression in the subjects with emphysema and the correlation with p53 levels in all groups.
As another part of the TRAIL apoptotic system, we evaluated TRAIL mRNA expression in five lung samples from each group that were representative of the mean in terms of TRAIL receptor protein expression and found that TRAIL mRNA levels were significantly lower in the lung parenchyma of smokers with or without emphysema than in nonemphysematous nonsmokers ( Figure 2E ), which is clearly a different pattern than that of TRAIL receptor protein expression (Figures 2A and 2B ). It is known that TRAIL is widely expressed in the lung; immune cells like macrophages and lymphocytes are major sources (25, 26) . Our results suggest that active tobacco smoking may be responsible for a decrease in the expression of TRAIL mRNA. Proulx and colleagues (27) have demonstrated that cigarette smoke extract can reduce the amount of TNF released from alveolar macrophages exposed to lipopolysaccharides. Therefore, it is possible that cigarette smoke has similar inhibitory effects on the expression of TRAIL, a member of the TNF family. Moreover, decreased TRAIL mRNA expression in the emphysematous lung may not be as important as the observed up-regulation of TRAIL receptors, p53, and Bax/Bcl-x L ratio, because a cell's response to TRAIL is more affected by intracellular modifications than by the amount of TRAIL in the cell environment (28) .
It is well known that most normal cells and some cancer/ transformed cells are resistant to TRAIL-mediated apoptosis . A549 cells were exposed to H 2 O 2 (500 mM) and/ or tumor necrosis factor (TNF) (10 ng/ml) for 12 hours. Cells were lysed and TNF-related apoptosis-inducing ligand (TRAIL)-R1, TRAIL-R2, and TRAIL-R3 protein levels were assessed by Western blot. Results are expressed as protein/b-actin ratio reported in fold increase of the control (no TNF and H 2 O 2 exposure). Bars represent mean (n 5 3) and error bars the SEM. Bars with different lowercase letters are significantly different (P , 0.05). White horizontal bars at the bottom of the graphs show that the y axis has been truncated. (29) . However, the resistance mechanisms have not all been identified and seem to differ among cell types (28) . We found that the expression of TRAIL-R3 protein was higher in lung parenchyma from subjects with emphysema and increased in H 2 O 2 -treated A549 cells (Figures 2B and 4C ). TRAIL-R3 is a decoy receptor that may confer TRAIL resistance (11, 28) . However, TRAIL-R1 and TRAIL-R2, two proapoptotic receptors, were also up-regulated in the same conditions and may enhance alveolar TRAIL sensitivity. Moreover, it is important to note that TRAIL sensitivity is not only based on TRAIL receptor expression (28). Hu and colleagues (30) showed that TRAIL-resistant LNCaP human prostate cancer cells treated with inorganic selenium, a reactive oxygen species-generating agent, became sensitive to TRAIL-mediated apoptosis despite the fact that TRAIL-R1 and TRAIL-R2 levels did not change. They observed that oxidative stress induced p53 activation and Bax up-regulation, as we did in our in vitro study ( Figures 1A and 1B) , and that TRAIL sensitization induced by oxidative stress was dependent on p53 activation and Bax translocation to mitochondria. On the basis of our ex vivo and in vitro observations and on the work of Hu and coworkers (30), higher TRAIL-R1, TRAIL-R2, and p53 levels, and Bax/Bcl-x L ratio may lead to oxidative stress-mediated TRAIL sensitivity, which could contribute to the increased alveolar apoptosis seen in emphysema.
Limitations in this study were restricted to the in vitro evaluation of the effects of oxidative stress on A549 cells. Short-term exposure to H 2 O 2 was used to reproduce the long-term chronic oxidative stress found in subjects with emphysema. However, the use of H 2 O 2 is one of the most common and widely accepted approaches for studying the effects of oxidative stress (8) , and the use of H 2 O 2 at concentrations up to 1,000 mM is common with A549 cells (31) (32) (33) . Moreover, trypan blue coloration showed that the concentrations used here were not affecting cells viability (data not shown).
Increased alveolar cell apoptosis, oxidative stress, and proinflammatory cytokines such as TNF in the lung of subjects with emphysema are well-established events (2) (3) (4) (5) (6) (7) 34) . However, the mechanisms linking those events are not as clear. In the present study, we found that, in general, p53 levels, the Bax/Bcl-x L ratio, and TRAIL-R1, TRAIL-R2, and TRAIL-R3 levels were higher in the lung parenchyma of subjects with emphysema than in nonemphysematous subjects. We also showed that treating A549 cells with H 2 O 2 and TNF reproduced the ex vivo results observed in the lung tissue of subjects with emphysema. These results are a first step toward exploring the involvement of transcription factor p53 and the TRAIL apoptotic system in the increase of alveolar apoptosis observed in emphysema. Studies on oxidative stress-mediated TRAIL sensitization and the mechanisms responsible for TRAIL receptor up-regulation will be required to fully decipher the role of the TRAIL apoptotic system in the pathogenesis of emphysema.
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